The Transmembrane Protease Serine 2 pipeline drugs market research report outlays comprehensive information on the Transmembrane Protease Serine 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Transmembrane Protease Serine 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, Respiratory, Hematological Disorders, and Oncology which include the indications Coronavirus Disease 2019 (COVID-19), Unspecified Influenza Virus Infections, Pneumonia, Acute Respiratory Distress Syndrome, Disseminated Intravascular Coagulation (DIC), and Metastatic Prostate Cancer. It also reviews key players involved in Transmembrane Protease Serine 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Transmembrane Protease Serine 2 pipeline targets constitutes close to 16 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 3, 2, 1, 5, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Transmembrane Protease Serine 2 overview
Transmembrane protease serine 2 (TMPRSS2) belongs to the serine protease family. The protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage. TMPRSS2 aid entry of viruses into host cells by proteolytically cleaving and activating viral envelope glycoproteins. Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1, or matriptase/ST14, leading to extracellular matrix disruption and metastasis of prostate cancer cells.
For a complete picture of Transmembrane Protease Serine 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
